Plasma hepcidin levels and anemia in old age. The Leiden 85-plus study

Haematologica

Volumn 98, Issue 3, 2013, Pages 448-454

  den Elzen, Wendy P J ^a   de Craen, Anton J M ^a   Wiegerinck, Erwin T ^b   Westendorp, Rudi G J ^a,c   Swinkels, Dorine W ^b   Gussekloo, Jacobijn ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Leyden Academy on Vitality and Ageing   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRITIN; FOLIC ACID; HEPCIDIN; INTERLEUKIN 6; IRON; TRANSFERRIN;

AGED; ANEMIA; ARTICLE; CALORIMETRY; COMORBIDITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGICAL PARAMETERS; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; SENESCENCE; SENSITIVITY ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; AGE; BLOOD; HEALTH SURVEY; NETHERLANDS; PROSPECTIVE STUDY; VERY ELDERLY;

AGE FACTORS; AGED, 80 AND OVER; ANEMIA; COMORBIDITY; FEMALE; HEPCIDINS; HUMANS; MALE; NETHERLANDS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES;

EID: 84874512115     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.068825     Document Type: Article

References (49)

1. den Elzen WP, Willems JM, Westendorp RG, de Craen AJ, Assendelft WJ, Gussekloo J. Effect of anemia and comorbidity on functional status and mortality in old age: results from the Leiden 85-plus Study. CMAJ. 2009;181(3-4):151-7.
2. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8): 2263-8.
3. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ. 2008;179(4):333-7.
4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.
5. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011; 57(12):1650-69.
6. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011; 62347-60.
7. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-8.
8. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113 (9):1271-6.
9. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3.
10. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA. 2002;99(7):4596-601.
11. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109(9):4038-44.
12. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105(4):1797-802.
13. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106(6):2196-9.
14. van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CM, van Riel PL, van Ede AE, Swinkels DW. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011;63(12): 3672-80.
15. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7):2461-3.
16. van Eijk LT, Kroot JJ, Tromp M, van der Hoeven JG, Swinkels DW, Pickkers P. Inflammation-induced hepcidin-25 is associated with the development of anemia in septic patients: an observational study. Crit Care. 2011;15(1):R9.
17. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9): 976-81.
18. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010;25(3):848-53.
19. Ukarma L, Johannes H, Beyer U, Zaug M, Osterwalder B, Scherhag A. Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin Chem. 2009;55 (7):1354-60.
20. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am. 2003;23 (1):15-39.
21. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL. The origins of age-related proinflammatory state. Blood. 2005;105(6):2294-9.
22. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, et al. Proinflammatory state, hepcidin and anemia in older persons. Blood. 2010;115(18):3810-6.
23. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol. 2005;184(2):361-70.
24. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW. (Pre)analytical imprecision, betweensubject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem. 2009;389(2): 124-9.
25. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56(10): 1570-9.
26. der Wiel AB, van Exel E, de Craen AJ, Gussekloo J, Lagaay AM, Knook DL, Westendorp RG. A high response is not essential to prevent selection bias: results from the Leiden 85-plus study. J Clin Epidemiol. 2002;55(11):1119-25.
27. Swinkels DW, Girelli D, Laarakkers C, Kroot J, Campostrini N, Kemna EH, Tjalsma H.Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE. 2008;3(7):e2706.
28. Samenwerkende Artsenlaboratoria en diagnostische centra in Nederland. Online SAN Memoboek voor diagnostiek in de eerstelijn, http://memoboek.dynapaper.nl. Accessed September 2011.
29. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1968;4055-37.
30. den Elzen WP, Westendorp RG, Frolich M, de Ruijter W, Assendelft WJ, Gussekloo J. Vitamin B12 and folate and the risk of anemia in old age. The Leiden 85-Plus Study. Arch Intern Med. 2008;168(20):2238-44.
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
32. van der Wiel Bootsma A, de Craen AJ, van Exel E, MacFarlane PW, Gussekloo J, Westendorp RG. Association between chronic diseases and disability in elderly subjects with low and high income: the Leiden 85-plus Study. Eur J Public Health. 2005;15(5):494-7.
33. Heeren TJ, Lagaay AM, von Beek WC, Rooymans HG, Hijmans W. Reference values for the Mini-Mental State Examination (MMSE) in octoand nonagenarians. J Am Geriatr Soc. 1990;38(10):1093-6.
34. Galesloot TE, Vermeulen SH, GeurtsMoespot AJ, Klaver SM, Kroot JJ, van TD, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117 (25):e218-e225.
35. Lee P, Gelbart T, Waalen J, Beutler E. The anemia of ageing is not associated with increased plasma hepcidin levels. Blood Cells Mol Dis. 2008;41(3):252-4.
36. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53(4):620-8.
37. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108(4): 1381-7.
38. Makipour S, Kanapuru B, Ershler WB. Unexplained anemia in the elderly. Semin Hematol. 2008;45(4):250-4.
39. Patel KV. Epidemiology of anemia in older adults. Semin Hematol. 2008;45(4):210-7.
40. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.
41. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25(4): 888-95.
42. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26323-42.
43. Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infect Immun. 2003;71(12):6693-700.
44. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806-10.
45. Vyoral D, Petrak J. Hepcidin: a direct link between iron metabolism and immunity. Int J Biochem Cell Biol. 2005;37(9):1768-73.
46. Troutt JS, Rudling M, Persson L, Stahle L, Angelin B, Butterfield AM, Schade AE, Cao G, Konrad RJ. Circulating human hepcidin25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem. 2012;58(8):1225-32.
47. www.hepcidinanalysis.com, accessed June 1, 2012.
48. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll AS, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 2009;113(21):5277-86.
49. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115 (17):3616-24.